The nucleic acid therapeutics market industry is projected to grow from USD Significant by 2032, exhibiting a compound annual growth rate (CAGR) of moderate during the forecast period (2023 - 2032). Nucleic acid therapeutics market growth has been driven by several key market drivers, including the creation of biological products, DNA therapies, and the growth of the pharmaceutical and healthcare sectors.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The potential of nucleic acid medicines to cure hereditary and chronic illnesses is driving up demand for them. DNA and RNA are examples of nucleic acids, which are vital molecules that are crucial for controlling gene expression and protein synthesis in cells. Furthermore, market growth will be fueled by an increase in the number of nucleic acid therapies approved by the FDA or the European Medicines Agency (EMA). In recent years, there has been a notable surge in the approval and development of nucleic acid medicines, encompassing RNA and DNA-based treatments. Technology advancements and our growing understanding of the genetic pathways behind many diseases are partly to blame for this. For example, Onpattro (patisiran), a small interfering RNA (siRNA) therapy, has been approved as a nucleic acid therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR). The FDA approved this treatment for RNA interference (RNAi) for the first time in 2018.
CDMOs can use a number of recent developments in manufacturing technology to increase productivity and cut expenses. The application of continuous manufacturing techniques is one such development. Instead of batch processing, which can be labor-intensive and need a large quantity of equipment, this method runs reactions in a continuous flow. Large amounts of starting materials and reagents are not required as frequently in continuous manufacturing, which also enables quicker processing times. The use of automated technologies for the purification and analysis of nucleic acids is another development. Automation can help to lower expenses, boost efficiency, and decrease errors while also increasing accuracy. Additionally, by enhancing the scalability of nucleic acid manufacturing, these systems can let CDMOs generate vast amounts of nucleic acids for research or commercial purposes. Thus, driving the nucleic acid therapeutics market revenue.
The Europe Nucleic Acid Therapeutics market segmentation, based on product includes Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others. The anti-sense oligonucleotides (ASOs) segment dominated the market mostly. Single-stranded, short RNA or DNA molecules known as antisense oligonucleotides (ASOs) can bind to specific messenger RNA (mRNA) sequences and either cause the targeted mRNA to decay or not translate into a protein. This property makes ASOs a potentially useful therapeutic strategy for a variety of conditions, including cancer, infectious illnesses, and genetic disorders.
The Europe Nucleic Acid Therapeutics market segmentation, based on application, includes Monogenetic Disorders and Multi-genetic Disorders. The monogenetic disorders category generated the most income due to the fact that the majority of diseases that are treated with nucleic acid therapies are hereditary and widespread. The release of recently developed and approved medicines for single gene disorders by major industry players is the main factor propelling the growth of the nucleic acid therapeutics market. Leading practitioners in the field are focusing on developing new strategies to deal with problems related to stability, gene quality, and off-targets in multi-genetic diseases.
Figure 1: Europe Nucleic Acid Therapeutics Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Europe Nucleic Acid Therapeutics market segmentation, based on end user, includes Hospitals and Clinics and Academic and Research Institutes. The hospitals and clinics category generated the most income. Customized medications are becoming more and more in demand as a result of the increased usage of treatments and vaccinations to address various chronic conditions. An additional factor driving this market segment is the rise in the number of visits to clinics and hospitals.
The Europe nucleic acid therapeutics market area will grow at a significant rate due to the growing acceptance of innovative nucleic acid therapeutics and the accessibility of nucleic acid extraction technologies. The market expansion in this region is at its pinnacle and is anticipated to stay that way for the duration of the projected period because all favorable variables are present. Additionally, the growing investments in the healthcare industry have pushed research into the treatment of numerous illnesses and disorders. Furthermore, this area holds the largest share of the European nucleic acid therapies market due to the presence of multiple startups and established companies, as well as FDA approvals.
Figure 2: EUROPE NUCLEIC ACID THERAPEUTICS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Nucleic Acid Therapeutics Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the nucleic acid therapeutics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, nucleic acid therapeutics industry must offer cost-effective items.
Key Companies in the nucleic acid therapeutics market include
| Report Attribute/Metric | Details |
| Market Size 2022 | Significant |
| Market Size 2023 | Significant |
| Market Size 2032 | Significant |
| Compound Annual Growth Rate (CAGR) | Moderate (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Application, End User, and Region |
| Region Covered | Europe |
| Countries Covered | German, France, UK, Italy, Spain |
| Key Companies Profiled | Sarpeta Therapeutics, Qaigen NV, Genzyme Sanofi, Copernicus, Merck KGaA, Agilent Technologies, Protagonist Therapeutics, Thermo Fisher Scientific, NOVARTIS AG., Benitec Biopharma, Silence Therapeutics, Arbutus Biopharma |
| Key Market Opportunities | ·      Accelerated Shift in the Pharmaceutical Industry to Innovative Biologics |
| Key Market Dynamics | ·      Elevated Incidence of Genetic Conditions ·      Rising Healthcare Industry Investments |
Frequently Asked Questions (FAQ) :
The Europe Nucleic Acid Therapeutics market size was valued at USD significant in 2022.
The market is projected to grow at a CAGR of moderate during the forecast period, 2023-2032.
The key players in the market are Sarpeta Therapeutics, Qaigen NV, Genzyme Sanofi, Copernicus, Merck KGaA, Agilent Technologies, Protagonist Therapeutics, Thermo Fisher Scientific, NOVARTIS AG., Benitec Biopharma, Silence Therapeutics, Arbutus Biopharma.
The Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers category dominated the market in 2022.
The Hospitals and Clinics category had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
